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MDM2 and MDMX are negative regulators of the tumor suppressor protein p53, and therefore confer tumor development and survival. 1, 2 MDM2 and MDMX bind to the N-terminal transactivation domain of p53 with high affinity to inhibit functions associated with regulating responsive gene expression. [3] [4] [5] [6] MDM2 has E3 ubiquitin ligase activity and thus also regulates the stability of p53 by proteasomal degradation, thereby conferring effective down-regulation of cellular p53 protein levels. [7] [8] [9] [10] MDMX has no ubiquitin ligase activity, yet forms an MDMX-MDM2 heterodimer via interaction between their C-terminal RING finger domains. This heterodimer stimulates MDM2-mediated ubiquitination of the p53 and subsequent degradation. [11] [12] [13] [14] As such, high expression of MDM2 and MDMX results in a reduction in the activity and expression level of the p53 in cancer cells. 15 Inhibitory compounds that block the interaction between MDM2-p53 and MDMX-p53 have been identified 16 using various types of high throughput screening technologies. 17 For example, MDM2-p53 interaction inhibitors, nutlin-1, -2, and -3, were identified by surface plasmon resonance (SPR) analysis. 18 SJ-172550 is an MDMX-p53 interaction inhibitor, which was identified by a fluorescence polarization (FP) assay.
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These facile technologies are based on the evaluation of inhibitory effects by compounds against p53 binding to MDM2/MDMX. Affinity-based screening is an alternative approach for the identification of potential inhibitors against protein-protein interactions (PPIs). 20 This approach explores PPI inhibitors against previously recognized binding pockets as well as search for potential binding molecules that interact with alternative or unexpected pockets present in the target proteins. The phage display method is an example of an affinity-based screening technique, which has been employed to identify peptide-based MDM2 binding peptides. 21 The microarray technology has also been used for the affinity-based screening of peptides and small-molecules, in which the potential hit compounds with affinity to the loaded protein can be selected based on fluorescent signals using a microarray scanner. 22 We have previously established chemical array screening as a novel method of small 4 molecule microarrays. On the chemical array, small molecules are immobilized at a variety of positions to a carbene-based photo-cross linker. 23 Using this photo-crosslinked chemical array technology, there have been some examples that have identified bioactive compounds such as carbonic anhydrase II inhibitors and a pirin-Bcl3 inhibitor, Tph A. 24, 25 In this study, we report a novel approach for the identification of peptidic inhibitors against MDM2-p53 and MDMX-p53 interactions.
There have been two reports on the synthesis of MDM2 and MDMX proteins by combining Boc-based solid-phase peptide synthesis (SPPS) with native chemical ligation. 21, 26 Although this approach would be applicable to large-sized protein synthesis, a more facile stepwise Fmoc-SPPS approach was undertaken for these proteins in this study (Scheme 1). The p53-binding domain of MDM2 and MDMX (designated MDM2 and MDMX , respectively) were synthesized by To validate the structures of the synthetic proteins, we evaluated circular dichroism (CD) spectra of MDM2 and MDMX ( Figure 1) . Negative bands at 208 nm and 222 nm indicated the presence of α-helix secondary structure elements, which is characteristic for MDM2 and MDMX, 5 and supported by previous crystal structure and CD analyses. 21, 27 To further verify the biological activity of the synthetic proteins, binding affinities of MDM2 and MDMX towards the p53 peptide sequence were evaluated by SPR analysis. Varying concentrations of MDM2 and MDMX proteins were analyzed by a NeutrAvidin-coated NLC sensor chip (BioRad) on which the biotinylated wild-type p53 peptide 19 (biotinyl-aminocaproyl-GSGSSQETFSDLWKLLPEN-NH2) was immobilized ( Figure 2 ). MDM2 and MDMX bound the p53 peptide with Kd values of 0.803 and 2.22 µM, respectively, which supported the correct folding of these proteins. towards the p53 peptide were 0.616 and 2.14 µM, respectively, indicating that N-terminal modification of synthetic MDM2 and MDMX had no effect on the folding of these proteins or the biological functions. 17 With these synthetic proteins in hand, we assessed the binding ability of MDM2 These dual inhibitors represent promising anti-cancer agent leads against cancer cells in which MDM2 and/or MDMX are overexpressed. 30 To gain insight into the effect on cell proliferation, growth inhibition by compounds 13 against human lung carcinoma-derived A549 cells was assessed. Compounds 1 and 3 showed no effect on cell growth at 30 µM, whereas cell growth was inhibited by compound 2 (EC50 = 13.7 µM).
Of note, in the screening process in this study, the biological data from FP assays did not necessarily correspond to the binding ability obtained in the initial microarray screening, possibly owing to structural modification of the molecules bound to the microarray and potential binding to other binding site(s) than the p53 binging pocket. However, the microarray technology successively facilitated the selection process and the identification of potential inhibitors. CD spectra of MDM2 and MDMX (4 M) were measured at room temperature in PBS containing 0.1 mM TCEP (pH 7.4). were insoluble at >30 M in the medium for growth inhibition assay.
